NASDAQ:CNSY Plus Therapeutics (CNSY) Stock Price, News & Analysis $1.88 +0.19 (+11.24%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$1.82 -0.05 (-2.93%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsNews and TrendsSEC Filings About Plus Therapeutics Stock (NASDAQ:CNSY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Plus Therapeutics alerts:Sign Up Key Stats Today's Range$1.66▼$1.9250-Day Range$1.56▼$3.8452-Week Range$1.49▼$18.89Volume111,658 shsAverage Volume184,551 shsMarket Capitalization$14.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s lead investigational product is RNL, also known as rhenium-186 nanoliposome, an experimental treatment designed to deliver radiation directly to tumors while limiting exposure to surrounding healthy tissue. Plus Therapeutics is primarily evaluating RNL in cancers of the central nervous system, including recurrent glioblastoma and leptomeningeal metastases. Its clinical development programs include the ReSPECT-GBM study for recurrent glioblastoma and the ReSPECT-LM program for leptomeningeal metastases associated with cancers such as breast and lung cancer. The company is headquartered in Austin, Texas, and conducts its development activities through clinical research and collaborations with medical institutions. Plus Therapeutics was previously known as Cytori Therapeutics before adopting its current name. Marc H. Hedrick has served as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Plus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreCNSY MarketRank™: 0.23318444561 of 5 starsPlus Therapeutics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.9 / 5Analyst RatingSell Consensus RatingPlus Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoveragePlus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Plus Therapeutics' stock forecast and price target. Earnings and Valuation0.7 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Plus Therapeutics are expected to grow in the coming year, from ($4.40) to ($3.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Plus Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPlus Therapeutics has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.12% of the float of Plus Therapeutics has been sold short.Short Interest Ratio / Days to CoverPlus Therapeutics has a short interest ratio ("days to cover") of 5.82.Change versus previous monthShort interest in Plus Therapeutics has recently increased by 14.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPlus Therapeutics does not currently pay a dividend.Dividend GrowthPlus Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.37 News SentimentPlus Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Plus Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for CNSY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Plus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.50% of the stock of Plus Therapeutics is held by insiders.Percentage Held by Institutions3.28% of the stock of Plus Therapeutics is held by institutions.Read more about Plus Therapeutics' insider trading history. Receive CNSY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNSY Stock News HeadlinesPlus Therapeutics (NASDAQ:CNSY) Shares Up 7.8% - Here's What HappenedOctober 10, 2026 | americanbankingnews.comCerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile TestsOctober 8, 2026 | globenewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.October 16 at 1:00 AM | Weiss Ratings (Ad)Cerenome Launches CNSide® CSF Molecular Profile TestsOctober 6, 2026 | globenewswire.comCerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform TranscriptSeptember 30, 2026 | seekingalpha.comCerenome Expects $1.55 Million in CNSide® Third Quarter Gross BillingsSeptember 30, 2026 | globenewswire.comCerenome to Hold CNSide® Business Update Call on September 30, 2026September 25, 2026 | globenewswire.comCerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered LivesSeptember 22, 2026 | globenewswire.comSee More Headlines CNSY Stock Analysis - Frequently Asked Questions How have CNSY shares performed this year? Plus Therapeutics' stock was trading at $3.91 on August 5, 2026. Since then, CNSY shares have decreased by 51.9% and is now trading at $1.88. How were Plus Therapeutics' earnings last quarter? Plus Therapeutics, Inc. (NASDAQ:CNSY) released its earnings results on Friday, August, 14th. The company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by $0.35. The company earned $0.41 million during the quarter. Plus Therapeutics had a negative net margin of 620.70% and a negative trailing twelve-month return on equity of 394.17%. How do I buy shares of Plus Therapeutics? Shares of CNSY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today10/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CNSY's financial health is in the Red zone, according to TradeSmith. CNSY has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:CNSY CIK1095981 Webwww.cerenome.com Phone(737) 255-7194Fax858-450-4335Employees28Year Founded1996Profitability EPS (Trailing Twelve Months)($3.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.39 million Net Margins-620.70% Pretax Margin-620.70% Return on Equity-394.17% Return on Assets-151.36% Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio0.65 Sales & Book Value Annual Sales$5.21 million Price / Sales2.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book2.61Miscellaneous Outstanding Shares7,590,000Free Float7,400,000Market Cap$14.27 million OptionableN/A Beta1.47 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CNSY) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersForget Nvidia, Tesla, AMD – This Is BiggerLuke Lango, once ranked the top stock picker out of 15,000 by TipRanks, called Nvidia the cream of the crop in...InvestorPlace | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredA simple options strategy that changed one trader's pathIan Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...TradeWins | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNSY Stock Alerts